Malaysia

Population 2017: 32 million

### Tuberculosis Profile

#### Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>1.3 (1.1–1.4)</td>
<td>4.3 (3.5–4.5)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.3 (0.22–0.38)</td>
<td>0.93 (0.69–1.2)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>29 (25–34)</td>
<td>93 (79–107)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.8 (1.5–2.1)</td>
<td>5.7 (4.6–6.6)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.49 (0.37–0.63)</td>
<td>1.5 (1.2–2)</td>
</tr>
</tbody>
</table>

#### Mortality (excludes HIV+TB)
- Number: 1.3 (1.1–1.4)
- Value: 4 (3.5–4.5)

#### Mortality (HIV+TB only)
- Number: 0.3 (0.22–0.38)
- Value: 0.93 (0.69–1.2)

#### Incidence (includes HIV+TB)
- Number: 29 (25–34)
- Value: 93 (79–107)

#### Incidence (HIV+TB only)
- Number: 1.8 (1.5–2.1)
- Value: 5.7 (4.6–6.6)

#### Incidence (MDR/RR-TB)**
- Number: 0.49 (0.37–0.63)
- Value: 1.5 (1.2–2)

#### Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>2 (1.5–2.4)</td>
<td>1.8 (1.4–2.2)</td>
<td>3.8 (3.1–4.4)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>9.2 (7–11)</td>
<td>16 (13–20)</td>
<td>26 (21–30)</td>
</tr>
<tr>
<td>Total</td>
<td>11 (8.8–13)</td>
<td>18 (14–22)</td>
<td>29 (25–34)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2017

- Total cases notified: 26,168
- Total new and relapse: 25,464
- % tested with rapid diagnostics at time of diagnosis: 87%
- % with known HIV status: 85%
- % bacteriologically confirmed among pulmonary: 74%

#### Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)
- TB patients facing catastrophic total costs: 0.05 (0.04–0.06)
- TB/HIV care in new and relapse TB patients, 2017: 1,356 (6%)
  - on antiretroviral therapy: 949 (70%)

#### Drug-resistant TB care, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>New cases</th>
<th>Previously treated cases</th>
<th>Total number***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated MDR/RR-TB cases among notified pulmonary TB cases</td>
<td>370</td>
<td></td>
<td>(290–460)</td>
</tr>
<tr>
<td>Estimated % of TB cases with MDR/RR-TB</td>
<td>1.5% (1.2–1.9)</td>
<td>3.1% (1.3–5.9)</td>
<td></td>
</tr>
<tr>
<td>% notified tested for rifampicin resistance</td>
<td>47%</td>
<td>46%</td>
<td>15,432</td>
</tr>
<tr>
<td>MDR/RR-TB cases tested for resistance to second-line drugs</td>
<td>65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed cases MDR/RR-TB: 352, XDR-TB: 1</td>
<td>Patients started on treatment ****</td>
<td>MDR/RR-TB: 97, XDR-TB: 0</td>
<td></td>
</tr>
</tbody>
</table>

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>Category</th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2016</td>
<td>80%</td>
<td>25,005</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2016</td>
<td>50%</td>
<td>736</td>
</tr>
<tr>
<td>HIV-positive TB cases registered in 2016</td>
<td>56%</td>
<td>1,406</td>
</tr>
<tr>
<td>MDR/RR-TB cases started on second-line treatment in 2015</td>
<td>41%</td>
<td>85</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2015</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

#### TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 79%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 100% (87–100)

#### TB financing, 2018

- National TB budget (US$ millions): 16
  - Funding source: 100% domestic, international, 0% unfunded

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2019-08-31

Data: www.who.int/tb/data